NewGenIvf Group (NIVFW) Financials
Newest figures come from the 10-K for FY2025, filed Aug 20, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NIVFW SEC filings page.
NewGenIvf Group (NIVFW) reported $4.7M in revenue for fiscal year 2025, down 13.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financing-supported balance-sheet reset sits beside severe operating-cost expansion and a net profit that does not convert to cash.
The earnings-quality break is unusually wide: FY2025 reported net income of$9.9M alongside operating income of-$10.7M and operating cash flow of-$10.9M , so the bottom-line gain did not represent cash generated by core operations. Financing cash flow of$19.0M and the swing from negative equity in FY2024 to$26.6M in FY2025 indicate that balance-sheet improvement came through financing and non-operating items rather than cash profitability.
Unit economics weakened: gross margin contracted from
The balance sheet moved from negative equity in FY2024 to
Financial Health Signals
NewGenIvf Group does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
NewGenIvf Group passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, NewGenIvf Group used $1.11 of operating cash (-$10.9M OCF vs $9.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
NewGenIvf Group reported an operating loss of $10.7M against $616K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
NewGenIvf Group held $759K in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
NIVFW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
NIVFW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q4'2410-K | Q4'2310-K | Q4'2210-K |
|---|---|---|---|---|
| Total Assets | $32.7M+814.6% | $3.6M-20.3% | $4.5M+54.5% | $2.9M |
| Current Assets | $7.4M+132.7% | $3.2M+29.0% | $2.5M+2.5% | $2.4M |
| Cash & Equivalents | $759K+65.7% | $458K+746.0% | $54K+96.3% | $28K |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Inventory | $335K+315.0% | $81K-36.0% | $126K+169.2% | $47K |
| Accounts Receivable | $167K+238.2% | $49K+425.3% | $9K-27.9% | $13K |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Total Liabilities | $6.7M+33.1% | $5.1M+307.6% | $1.2M-55.7% | $2.8M |
| Current Liabilities | $2.4M-13.0% | $2.7M+142.4% | $1.1M-56.1% | $2.6M |
| Non-Current Liabilities | $4.4M+86.8% | $2.3M+1866.0% | $119K-52.1% | $249K |
| Total Equity | $26.6M+2639.7% | -$1.0M-128.1% | $3.7M+563.4% | $563K |
| Retained Earnings | $8.9M+1002.0% | -$986K-113.7% | -$461K+22.0% | -$592K |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
NIVFW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
NIVFW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Where NewGenIvf Group Ranks
Frequently Asked Questions
What is NewGenIvf Group's annual revenue?
NewGenIvf Group (NIVFW) reported $4.7M in total revenue for fiscal year 2025. This represents a -13.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is NewGenIvf Group's revenue growing?
NewGenIvf Group (NIVFW) revenue declined by 13.0% year-over-year, from $5.4M to $4.7M in fiscal year 2025.
Is NewGenIvf Group profitable?
Yes, NewGenIvf Group (NIVFW) reported a net income of $9.9M in fiscal year 2025.
What is NewGenIvf Group's EBITDA?
NewGenIvf Group (NIVFW) had EBITDA of -$10.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is NewGenIvf Group's gross margin?
NewGenIvf Group (NIVFW) had a gross margin of 20.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is NewGenIvf Group's return on equity (ROE)?
NewGenIvf Group (NIVFW) has a return on equity of 37.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is NewGenIvf Group's free cash flow?
NewGenIvf Group (NIVFW) recorded an outflow of $11.1M in free cash flow during fiscal year 2025. This represents a -33.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is NewGenIvf Group's operating cash flow?
NewGenIvf Group (NIVFW) recorded an outflow of $10.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are NewGenIvf Group's total assets?
NewGenIvf Group (NIVFW) had $32.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are NewGenIvf Group's capital expenditures?
NewGenIvf Group (NIVFW) invested $135K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is NewGenIvf Group's current ratio?
NewGenIvf Group (NIVFW) had a current ratio of 3.12 as of fiscal year 2025, which is generally considered healthy.
What is NewGenIvf Group's debt-to-equity ratio?
NewGenIvf Group (NIVFW) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is NewGenIvf Group's return on assets (ROA)?
NewGenIvf Group (NIVFW) had a return on assets of 30.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is NewGenIvf Group's Piotroski F-Score?
NewGenIvf Group (NIVFW) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are NewGenIvf Group's earnings high quality?
For every $1 of reported earnings, NewGenIvf Group (NIVFW) used $1.11 of operating cash (-$10.9M OCF vs $9.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can NewGenIvf Group cover its interest payments?
NewGenIvf Group (NIVFW) reported an operating loss of $10.7M against $616K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.